Reference Detail

Ref Type
Authors Suzanne George, Michael C. Heinrich, Albiruni Ryan Abdul Razak, Ping Chi, Michael S. Gordon, Kristen N. Ganjoo, Margaret von Mehren, Neeta Somaiah, Jonathan C. Trent, Ying Su, Rodrigo Ruiz-Soto, Oliver Rosen, Filip Janku
Title Mutation profile of drug resistant gastrointestinal stromal tumor (GIST) patients (pts) enrolled in the phase 1 study of DCC-2618.
Journal Journal of Clinical Oncology
Abstract Text Journal of Clinical Oncology 36, no. 15_suppl (May 20 2018) 11511-11511


  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"


  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Treatment Approach
Gene Name Source Synonyms Protein Domains Gene Description Gene Role
Therapy Name Drugs Efficacy Evidence Clinical Trials
Drug Name Trade Name Synonyms Drug Classes Drug Description
Variant Impact Protein Effect Variant Description Associated with drug Resistance
Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
Unknown unknown gastrointestinal stromal tumor not applicable DCC-2618 Phase I Actionable In a Phase I study, DCC-2618 treatment resulted in an overall response rate of 16% (16/99) in patients with drug resistant gastrointestinal stromal tumors, 71% (55/77) of analyzed patients harbored baseline KIT or PDGFRA activating mutations (Journal of Clinical Oncology 36, no. 15_suppl (May 20 2018) 11511-11511; NCT02571036). detail...